Approaches to the choice of anticoagulant therapy in the treatment of patients with combination of atrial fibrillation with coronary heart disease...
Остроумова О. Д., Кочетков А. И., Орлова И. Y., Смолярчук Е. А., Павлова Й. С.
Рациональная фармакотерапия в кардиологии
Т. 14, Вып. 3, С. 441-450
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.20996/1819-6446-2018-14-3-441-450
Аннотация:
The choice of anticoagulant therapy in patients with atrial fibrillation (AF) and concomitant diseases - coronary heart disease (CHD), including acute coronary syndrome (ACS) in history, peripheral arterial disease (PAD), is discussed in the article. The overall mortality and incidence of myocardial infarction in patients with CHD and AF is higher than in patients with AF without CHD. Patients with AF and PAD compared to patients with AF without PAD have higher risks both stroke and systemic embolism. The prescription of triple antithrombotic therapy is necessary for patients with a combination of AF and CHD who underwent percutaneous coronary interventions (in ACS or elective surgery). The possibility of prescription and duration, the choice of specific drugs and their doses should be determined individually, based on the risks of ischemic events associated with stenting, the risk of ischemic stroke and bleeding. Use of new oral anticoagulants (NOAC) instead of vitamin K antagonists (
Ключевые слова:
Apixaban; Atrial fibrillation; Coronary artery disease; Direct oral anticoagulant; Peripheral artery disease
acetylsalicylic acid; apixaban; clopidogrel; proton pump inhibitor; warfarin; acute coronary syndrome; anticoagulant therapy; Article; atherosclerosis; atrial fibrillation; bleeding; cardiovascular mortality; cerebrovascular accident; clinical effectiveness; drug safety; elective surgery; embolism; heart infarction; high risk patient; human; incidence; ischemic heart disease; percutaneous coronary intervention; peripheral occlusive artery disease; prescription; risk benefit analysis; treatment duration; treatment planning
Язык текста: Русский
ISSN: 2225-3653
Остроумова О. Д. Ольга Дмитриевна 1968-
Кочетков А. И.
Орлова И. Y.
Смолярчук Е. А. Елена Анатольевна 1974-
Павлова Й. С.
Ostroumova O. D. Ol`ga Dmitrievna 1968-
Kochetkov A. I.
Orlova I. Y.
Smolyarchuk E. A. Elena Anatolyevna 1974-
Pavlova J. S.
Approaches to the choice of anticoagulant therapy in the treatment of patients with combination of atrial fibrillation with coronary heart disease or peripheral atherosclerosis: Potential of apixaban
Approaches to the choice of anticoagulant therapy in the treatment of patients with combination of atrial fibrillation with coronary heart disease...
Текст визуальный непосредственный
Рациональная фармакотерапия в кардиологии
Столичная издательская компания
Т. 14, Вып. 3 С. 441-450
2018
Статья
Apixaban Atrial fibrillation Coronary artery disease Direct oral anticoagulant Peripheral artery disease
acetylsalicylic acid apixaban clopidogrel proton pump inhibitor warfarin acute coronary syndrome anticoagulant therapy Article atherosclerosis atrial fibrillation bleeding cardiovascular mortality cerebrovascular accident clinical effectiveness drug safety elective surgery embolism heart infarction high risk patient human incidence ischemic heart disease percutaneous coronary intervention peripheral occlusive artery disease prescription risk benefit analysis treatment duration treatment planning
The choice of anticoagulant therapy in patients with atrial fibrillation (AF) and concomitant diseases - coronary heart disease (CHD), including acute coronary syndrome (ACS) in history, peripheral arterial disease (PAD), is discussed in the article. The overall mortality and incidence of myocardial infarction in patients with CHD and AF is higher than in patients with AF without CHD. Patients with AF and PAD compared to patients with AF without PAD have higher risks both stroke and systemic embolism. The prescription of triple antithrombotic therapy is necessary for patients with a combination of AF and CHD who underwent percutaneous coronary interventions (in ACS or elective surgery). The possibility of prescription and duration, the choice of specific drugs and their doses should be determined individually, based on the risks of ischemic events associated with stenting, the risk of ischemic stroke and bleeding. Use of new oral anticoagulants (NOAC) instead of vitamin K antagonists (